

Table of Contents

- EXECUTIVE SUMMARY
 - The diagnostic-centric healthcare delivery model
 - IV2D Enabling Technologies
 - IV2D Initiatives at Academic Medical Centers
 - Siemens – Medical Diagnostics and Service Model
 - GE Healthcare’s Early Health Model
 - Other Imaging Companies Entering the IVD Market
 - Development Perspectives and Market Outlook

- The Diagnostic-Centric Healthcare Delivery Model
 - Summary
 - Introduction
 - Integrated diagnostics
 - Biomarkers

- IV2D Enabling Technologies
 - Summary
 - Introduction
 - Neurodegenerative disease
 - Alzheimer’s disease
 - Parkinson’s disease
 - Cancer
 - Mapping HER-2 positive cells
 - ¹¹C-choline PET/CT
 - Dual labels
 - Insulin-like growth factor
 - Cardiovascular disease
 - Troponin/CT Angiography
 - Conclusions

- IV2D Initiatives at Academic Medical Centers
 - Summary
 - Introduction
 - The Comprehensive Cancer Imaging Centre, London
 - Centre for Molecular Imaging, Australia
 - The Mayo Clinic, US
 - Conclusions

- Siemens – Medical diagnostics and service model
 - Summary
 - Introduction
 - Disease areas

- Cardiovascular
 - Oncology
 - Siemens' technologies
 - Diagnostics IT
 - Siemens information technology
 - Siemens molecular diagnostic assays
 - Integrated diagnostics
 - The customer's perspective
 - 2009 Molecular Summit, Philadelphia, USA 2009
 - Susquehanna Health
 - Conclusions
- GE Healthcare's early health model
 - Summary
 - Introduction
 - Early healthcare
 - "Healthymagination"
 - Digital imaging
 - Omnyx Integrated Digital Pathology solution (IDP)
 - GE and Eli Lilly
 - GE and VirtualScopics
 - GE and Merck
 - GE acquires Orbitech
 - The PredictAD Project
 - GE and Clariant
 - GE and ONI Medical Systems
 - Conclusions
- Other imaging companies entering the IVD market
 - Summary
 - Introduction
 - Philips Healthcare and Biomerieux
 - HistoRx
 - Bayer Schering Pharma
 - Imaging Diagnostic Systems
 - Given Imaging
 - AION Diagnostics
- Development Perspectives and Market Outlook
 - Summary
 - Introduction
 - Integrated diagnostics
 - Emerging developments
 - Breast cancer biomarkers
 - Alzheimer's disease
 - Market forecasts
 - Biomarkers and risks
 - Driving changes
 - Bibliography

- TABLES
 - Table: Breast cancer biomarkers indicated for use in the clinic by the American Society of Clinical Oncology (ASCO)
 - Table: Siemens dedicated clinical chemistry systems for cardiovascular disease
 - Table: Siemens immunoassays for cardiovascular disease
 - Table: Siemens haemostasis assays for cardiovascular disease
 - Table: Siemens integrated diagnostic systems for cardiovascular disease
 - Table: Siemens point-of-care diagnostics for cardiovascular disease
 - Table: Siemens diagnostic detection systems
 - Table: GE core healthcare capabilities
 - Table: Worldwide In vitro diagnostic sales by country 2009-2015, (\$bn)
 - Table: Worldwide In vitro diagnostic sales by application 2009-2015, (\$bn)
- FIGURES
 - Figure: The drivers shaping integration in medical diagnostics
 - Figure: Biomarkers with utility in the detection, diagnosis and treatment of breast cancer
 - Figure: Sources of biomarkers reported with utility in the detection, diagnosis and treatment of breast cancer
 - Figure: Types of biomarkers with utility in the detection or diagnosis of breast cancer
 - Figure: Single and multiple biomarkers in breast cancer
 - Figure: Use of [18F]fluorothymidine (18F-FLT)PET in breast cancer
 - Figure: Siemens medical diagnostic IT systems
 - Figure: Siemens diagnostic systems organizational structure
 - Figure: Siemens diagnostic IT organizational structure
 - Figure: Siemens diagnostic detection systems
 - Figure: GE's Vscan Visualization Tool
 - Figure: Omnyx Integrated Digital Pathology solution (IDP)
 - Figure: The Magnotech principle
 - Figure: Required capabilities of integrated diagnostic technologies
 - Figure: Sources of biomarkers with utility in the detection or diagnosis of breast cancer
 - Figure: Types of biomarkers with utility in the detection or diagnosis of breast cancer